Catalyst
Slingshot members are tracking this event:
Array Discontinues Phase 3 MILO Trial Evaluating MEK162 (ARRY-162) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
ARRY |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 01, 2016
Occurred Source:
http://www.prnewswire.com/news-releases/array-biopharma-announces-decision-to-discontinue-milo-study-in-ovarian-cancer-300244593.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Data, Mek162 (arry-162), Milo Trial, Lgsoc, Ovarian Cancer